Stevanato Group S.p.A. (NYSE:STVN) Shares Acquired by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC increased its position in Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 1.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,189,926 shares of the company's stock after acquiring an additional 106,930 shares during the period. Stevanato Group makes up about 2.5% of Conestoga Capital Advisors LLC's investment portfolio, making the stock its 14th biggest position. Conestoga Capital Advisors LLC owned approximately 2.70% of Stevanato Group worth $167,238,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Van Berkom & Associates Inc. purchased a new stake in Stevanato Group during the fourth quarter worth $39,000. Johnson Financial Group Inc. acquired a new position in shares of Stevanato Group during the 4th quarter worth $41,000. Wells Fargo & Company MN boosted its position in shares of Stevanato Group by 680.3% in the 4th quarter. Wells Fargo & Company MN now owns 3,246 shares of the company's stock worth $71,000 after buying an additional 2,830 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Stevanato Group by 1,457.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company's stock valued at $123,000 after acquiring an additional 5,291 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in Stevanato Group by 202.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,413 shares of the company's stock valued at $162,000 after acquiring an additional 4,965 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts have recently commented on STVN shares. William Blair reiterated an "outperform" rating on shares of Stevanato Group in a research report on Friday, March 7th. Stephens upgraded Stevanato Group to a "strong-buy" rating in a report on Monday, April 21st. Finally, UBS Group dropped their price target on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of €25.70 ($29.54).

Stevanato Group Trading Down 1.6%

Shares of NYSE:STVN traded down €0.37 ($0.43) during trading on Friday, reaching €23.38 ($26.87). The stock had a trading volume of 377,743 shares, compared to its average volume of 340,512. The company has a quick ratio of 1.26, a current ratio of 1.83 and a debt-to-equity ratio of 0.22. The stock has a market cap of $7.08 billion, a P/E ratio of 45.84, a PEG ratio of 2.27 and a beta of 0.53. The business has a fifty day moving average price of €22.74 and a 200-day moving average price of €21.72. Stevanato Group S.p.A. has a fifty-two week low of €16.56 ($19.03) and a fifty-two week high of €25.75 ($29.60).

Stevanato Group Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Thursday, July 17th. Stockholders of record on Thursday, June 5th will be given a $0.0613 dividend. The ex-dividend date of this dividend is Thursday, June 5th. This represents a dividend yield of 0.3%. This is an increase from Stevanato Group's previous annual dividend of $0.05.

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.